Johnson & Johnson (JNJ) — closed signal from September 20, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 19, 2025.
Predicted vs. what happened
What happened
Reached its target in 54 days.
The thesis — published September 20, 2025
JNJ is a steadier healthcare name. Several new U.S. drug approvals this week add fresh momentum and improve the mood around its medicine business. The price has slipped and interest from buyers looks solid, so this area can be a practical place to start a position, with the dividend helping cushion bumps. Over the next 1-3 months a modest recovery is reasonable, though drug pricing pressure, copycat rivals, and shifts away from safe stocks can limit gains.
Primary drivers
- New drug approvals this week strengthen confidence in JNJ's pipeline
- Price looks washed out, raising chances of a short-term bounce in the weeks ahead
- Reliable dividend helps soften downturns and rewards patient holders
- Defensive business can steady a portfolio when markets get choppy
How it played out
JNJ: target reached in 54 days
Lyra published JNJ at $175.08 on 2025-09-20 with an expected gain of 11% over a short-term window. The thesis pointed to new U.S. drug approvals, a washed-out price setup, buyer interest, the dividend, and a defensive business. It also noted drug pricing pressure, copycat rivals, and shifts away from safer stocks as limits on gains.
Inside the window, JNJ reached the $193.11 target in 54 days. The stock later peaked at $215.19 on 2025-12-15, with a 22.9% gain. It ended the window at $206.37. The thesis played out, and the move went beyond the target.
What happened during the window
On 2025-10-14, Johnson & Johnson reported third-quarter revenue of $23.99 billion and adjusted EPS of $2.80, and it announced plans to separate its orthopedics business. On 2025-11-17, Johnson & Johnson announced an agreement to acquire Halda Therapeutics for $3.05 billion in cash.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.